Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Receives $15.33 Average PT from Brokerages

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have been assigned an average rating of “Moderate Buy” from the four research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $14.00.

RADX has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Thursday, January 22nd. Wall Street Zen cut shares of Radiopharm Theranostics to a “strong sell” rating in a research report on Friday, January 23rd. Finally, B. Riley Financial reissued a “buy” rating and issued a $16.00 price target (up from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th.

Radiopharm Theranostics Trading Up 0.4%

Shares of RADX stock opened at $4.72 on Friday. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25. The business’s 50 day moving average price is $4.97 and its 200-day moving average price is $5.33.

Radiopharm Theranostics (NASDAQ:RADX) last announced its earnings results on Wednesday, January 28th. The company reported ($1.58) EPS for the quarter. The company had revenue of $0.46 million during the quarter.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. bought a new stake in shares of Radiopharm Theranostics during the second quarter valued at approximately $37,000. Marex Group plc bought a new position in Radiopharm Theranostics in the fourth quarter worth $54,000. Virtu Financial LLC purchased a new position in Radiopharm Theranostics during the fourth quarter valued at $76,000. Finally, Jane Street Group LLC purchased a new position in Radiopharm Theranostics during the fourth quarter valued at $76,000.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.